Table 1.
Oncolytic viruses in TMN clinical trials
| Virus | Genome | Genetic alterations | Delivery | Combination | Phase | References |
|---|---|---|---|---|---|---|
| Adenovirus | dsDNA | P53 (rAD-p53) | IT | Radioactive iodine/ Surgery | IV | 24 |
| P53 (ONYX-015) | IT | Cisplatin/5-fluorouracil | Marketed | 27 | ||
| Fas-c (VB-111) | IV | Anti-angiogenic agent | II | 29 | ||
| Reovirus | dsRNA | Natural strain (RT3D) | IT | Low-dose radiation/ | II | 35 |
| IT/IV | Gemcitabine/Carboplatin/Paclitaxel/Docetaxel | III | 37. 38 | |||
| Herpes simplex virus | dsDNA | N/A | ||||
| Vaccina virus | dsDNA | N/A | ||||
| New castle disease virus | ssRNA | N/A | ||||
| Vesicular virus | ssRNA | N/A | ||||
| Measles virus | ssRNA | N/A | ||||
| Retrovirus | ssRNA | N/A |
Abbreviation:
IT, Intra-tumor injection.
IV, Intra-venous injection.